Related Experiment Video
Updated: Oct 3, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Off-target drug repurposing for rare and ultra-rare cancers: towards a scalable therapeutic framework
Gehan Premaratne1, Malaka Ameratunga1,2
1Alfred Hospital, Melbourne, VIC, Australia.
Abstract:
Drug repurposing represents a pragmatic strategy for patients with cancer who have limited standard-of-care options. Traditional in silico or functional repurposing approaches often rely on well-characterised protein targets or validated experimental models, which are sparsely available in rare cancer settings and impractical within clinically relevant timeframes. Tumour-agnostic biomarker-driven strategies, by contrast, offer more timely workflows for integration into routine oncology practice, but have largely been dominated by 'on-target' approaches that may be less applicable to rare cancers frequently lacking canonical targetable mutations. However, emerging pharmacological evidence demonstrates that many anticancer agents engage a broader target landscape, creating opportunities for 'off-target' repurposing against non-canonical tumour dependencies. Although less established, we contend 'off-target' repurposing remains a potentially important strategy offering therapeutic hope to patients with rare cancers for whom no standard options, targetable biomarkers, or disease-specific trials exist. This perspective explores emerging evidence surrounding 'off-target' repurposing as a strategy, as well as evaluating recent criticisms of off-target low-evidence genomic matching in precision oncology literature. By doing so, we advocate for development of rigorously designed prospective clinical trials to examine 'off target' strategies, centred in safety of participants, evidence generation, and accessibility. Such frameworks require embedding off-target candidates within trial designs suited to small heterogeneous cohorts, with built-in mechanisms for evidence generation and access to therapies. We propose safe implementation should incorporate longitudinal monitoring, and parallel orthogonal validation to strengthen biological and pharmacological plausibility, refine drug and dose selection, and inform adaptive treatment modification over time.
More Related Videos
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
Drug Discovery: Overview
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...